31.42 USD
▲-0.31+0.93%
盘后 30.31 -2.63%
2026-08-03
市值
$1.98B
市盈率
—
EPS
-8.82
股息率
—
52 周区间
13.50 – 44.60
成交量
378.12K
Beta
—
目标价
43.50
52W 低 13.5052W 高 44.60
价格走势
公司简介
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an ext...